Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors

Oncotelic Therapeutics, Inc.

Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.
Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.
OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.
CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.